Seven Eight Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-25,809
| Closed | -$3.86M | – | 678 |
|
|
2024
Q1 | $3.86M | Buy |
25,809
+20,572
| +393% | +$3.07M | 0.4% | 61 |
|
|
2023
Q4 | $1M | Buy |
+5,237
| New | +$1M | 0.12% | 253 |
|
|
2023
Q2 | – | Sell |
-2,320
| Closed | -$465K | – | 484 |
|
|
2023
Q1 | $465K | Buy |
+2,320
| New | +$465K | 0.1% | 254 |
|
|
2022
Q4 | – | Sell |
-4,921
| Closed | -$985K | – | 401 |
|
|
2022
Q3 | $985K | Buy |
+4,921
| New | +$985K | 0.2% | 159 |
|
|
2022
Q2 | – | Sell |
-1,764
| Closed | -$288K | – | 380 |
|
|
2022
Q1 | $288K | Buy |
+1,764
| New | +$288K | 0.04% | 416 |
|
|
2019
Q4 | – | Sell |
-6,684
| Closed | -$538K | – | 613 |
|
|
2019
Q3 | $538K | Buy |
+6,684
| New | +$538K | 0.03% | 509 |
|
|
2018
Q3 | – | Sell |
-10,484
| Closed | -$1.03M | – | 560 |
|
|
2018
Q2 | $1.03M | Buy |
+10,484
| New | +$1.03M | 0.07% | 280 |
|
|
2017
Q4 | – | Sell |
-21,584
| Closed | -$2.54M | – | 444 |
|
|
2017
Q3 | $2.54M | Buy |
+21,584
| New | +$2.54M | 0.31% | 109 |
|
|
2016
Q2 | – | Sell |
-2,700
| Closed | -$169K | – | 529 |
|
|
2016
Q1 | $169K | Buy |
2,700
+1,800
| +200% | +$113K | 0.07% | 329 |
|
|
2015
Q4 | $85K | Buy |
+900
| New | +$85K | 0.06% | 376 |
|
|
2015
Q3 | – | Sell |
-400
| Closed | -$48K | – | 521 |
|
|
2015
Q2 | $48K | Sell |
400
-800
| -67% | -$96K | 0.06% | 335 |
|
|
2015
Q1 | $125K | Buy |
+1,200
| New | +$125K | 0.21% | 171 |
|